Opportunity Information: Apply for PAR 14 184
Apply for PAR 14 184
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "National Cooperative Drug Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242 Mental Health Research Grants 93.273 Alcohol Research Programs 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Apr 21, 2014 and posted on Apr 21, 2014.
- Applicants must submit their applications by Feb 23, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Independent school districts Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) For profit organizations other than small businesses County governments Special district governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education State governments Native American tribal organizations (other than Federally recognized tribal governments) City or township governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The National Cooperative Drug Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (U01) is a National Institutes of Health (NIH) cooperative agreement funding opportunity designed to push promising neuroscience and addiction science discoveries toward real therapeutic candidates. The central idea is to form multidisciplinary, milestone-driven research groups or partnerships that can move more quickly than a single lab acting alone, especially when the work spans target validation, medicinal chemistry, preclinical testing, and early clinical evaluation. The program focuses on pharmacological agents that can treat mental disorders and drug or alcohol addiction, while also supporting the creation of research tools (such as novel ligands) that help clarify disease biology and validate drug targets.
The program has several practical objectives that reflect the full early pipeline of drug development. First, it aims to accelerate innovative drug discovery, meaning it supports rational design and systematic optimization of candidate compounds rather than exploratory work without a clear translational endpoint. Second, it explicitly supports development of pharmacologic tools that can be used in both basic and clinical research to better understand mental disorders or substance use disorders; these tools can include ligands or compounds that selectively engage a target to test whether that target is actually relevant in vivo. Third, the opportunity emphasizes developing and validating tools and methods that enable experimental therapeutic studies of new candidates, which typically includes proof-of-concept studies, biomarker development or validation, and other translational measures that strengthen the case for a candidate entering humans. Finally, it supports early phase human clinical testing when appropriate, with the goal of rapidly assessing safety and early signals of efficacy for promising drug candidates, including new indications for agents that are already IND-ready.
A defining feature of this opportunity is that it is a cooperative agreement (U01), not a standard research project grant. In practice, that means NIH expects to have substantial scientific and programmatic involvement during the award period. Projects are generally expected to be organized around clear development plans, measurable deliverables, and coordinated team science. The announcement also strongly encourages partnerships between academia and industry, reflecting the reality that moving from discovery to development often requires capabilities common in industry settings, such as advanced medicinal chemistry, formulation, scalable synthesis, regulatory strategy, toxicology planning, and experience with IND-enabling packages and early clinical operations. The program is also explicitly open to applications that develop novel ligands as tools to characterize existing targets more deeply or to validate new targets, which can be essential when the field needs better target engagement measures, selectivity tools, or compounds that can be used in mechanistic studies.
Administratively, this funding opportunity is listed as PAR-14-184 and was posted April 21, 2014, with an original and final closing date of February 23, 2017, and an archive date of March 26, 2017. It falls under NIH’s discretionary grant programs and is associated with CFDA numbers 93.242 (Mental Health Research Grants), 93.273 (Alcohol Research Programs), and 93.279 (Drug Abuse and Addiction Research Programs). Cost sharing is not required, which lowers barriers for academic institutions and other organizations that may not have matching funds.
Eligibility is broad and includes many types of organizations capable of contributing to translational drug discovery and early development. Eligible applicants include public and private institutions of higher education, nonprofits with and without 501(c)(3) status, small businesses and other for-profit organizations (including those that are not small businesses), state and local governments (such as county and city governments and special district governments), federally recognized tribal governments and other tribal organizations, public housing authorities/Indian housing authorities, and independent school districts. The announcement also highlights additional eligible applicants such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian-serving institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), faith-based or community-based organizations, regional organizations, agencies of the federal government, and U.S. territories or possessions. Importantly, foreign components are allowed as defined in the NIH Grants Policy Statement, which can enable specialized collaborations when key expertise or resources are outside the United States.
Overall, this opportunity is best understood as a structured, team-based NIH mechanism intended to de-risk and speed up the path from mechanistic insight to testable therapeutic hypotheses in humans. It supports projects that can credibly advance a candidate agent through discovery and preclinical development and, when justified, into early clinical proof-of-concept, while also valuing tool compounds and ligands that strengthen the broader research ecosystem by enabling target characterization and validation. The full archived announcement and details were hosted by NIH at http://grants.nih.gov/grants/guide/pa-files/PAR-14-184.html, with technical access support routed through the NIH Office of Extramural Research webmaster contact.
Frequently Asked Questions (FAQs)
What is the National Cooperative Drug Discovery/Development Groups (NCDDG) program?
The National Cooperative Drug Discovery/Development Groups (NCDDG) program is an NIH funding opportunity that supports multidisciplinary, milestone-driven research groups focused on advancing promising neuroscience and addiction science discoveries toward real therapeutic candidates.
What is the full title of this funding opportunity?
The opportunity is titled "The National Cooperative Drug Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (U01)."
What NIH mechanism is used for this award?
This opportunity uses a U01 cooperative agreement mechanism, meaning NIH expects substantial scientific and programmatic involvement during the award period.
How is a U01 cooperative agreement different from a standard research grant?
Because it is a cooperative agreement (U01), NIH is expected to have substantial involvement, and projects are generally organized around clear development plans, measurable deliverables, and coordinated team science rather than operating as an independent, investigator-directed project typical of standard research grants.
What types of research does this program support?
The program supports translational drug discovery and early development activities, including target validation, medicinal chemistry, preclinical testing, and early clinical evaluation when appropriate.
What diseases or conditions are the focus of this program?
The focus is on pharmacological agents for the treatment of mental disorders and drug or alcohol addiction (substance use disorders).
Does the program only fund new drug candidates?
No. The program supports advancing candidate compounds through discovery and preclinical development and can also support early phase human clinical testing for promising candidates, including new indications for agents that are already IND-ready.
What is meant by "accelerate innovative drug discovery" in this program?
The program emphasizes rational design and systematic optimization of candidate compounds with a clear translational endpoint, rather than exploratory work without a defined path toward a therapeutic candidate.
Does this opportunity support development of research tools?
Yes. It explicitly supports development of pharmacologic tools for basic and clinical research, such as novel ligands or compounds that selectively engage a target to help clarify disease biology and validate drug targets.
What kinds of tool compounds are encouraged?
Applications may include novel ligands and other selective compounds that help characterize existing targets more deeply or validate new targets, including tools that enable target engagement measures, selectivity testing, and mechanistic studies.
Does the program support biomarker development or validation?
Yes. The program emphasizes developing and validating tools and methods that enable experimental therapeutic studies of new candidates, which can include proof-of-concept studies and biomarker development or validation.
Does the program support early phase clinical trials?
Yes, when appropriate. The program supports early phase human clinical testing intended to rapidly assess safety and early signals of efficacy for promising candidates.
What is the purpose of milestone-driven, team-based structure?
The intent is to move more quickly than a single lab acting alone, particularly when the work spans multiple drug development functions such as target validation, medicinal chemistry, preclinical testing, and early clinical evaluation.
Are academia-industry partnerships encouraged?
Yes. The announcement strongly encourages partnerships between academia and industry to reflect the capabilities often needed for drug discovery and development, such as advanced medicinal chemistry, formulation, scalable synthesis, regulatory strategy, toxicology planning, and IND-enabling and early clinical operations experience.
What is the FOA number for this opportunity?
The Funding Opportunity Announcement (FOA) number is PAR-14-184.
When was this FOA posted, and what were the closing dates?
It was posted on April 21, 2014. The original and final closing date was February 23, 2017. The archive date was March 26, 2017.
Is this funding opportunity still active?
Based on the provided information, the FOA has a final closing date of February 23, 2017 and an archive date of March 26, 2017, indicating it is archived.
What CFDA numbers are associated with this program?
The opportunity is associated with CFDA 93.242 (Mental Health Research Grants), 93.273 (Alcohol Research Programs), and 93.279 (Drug Abuse and Addiction Research Programs).
Is cost sharing (matching funds) required?
No. Cost sharing is not required.
Who is eligible to apply?
Eligibility is broad and includes public and private institutions of higher education, nonprofits with and without 501(c)(3) status, small businesses and other for-profit organizations (including those that are not small businesses), and various government entities and tribal organizations, among others.
Are for-profit organizations eligible?
Yes. Small businesses and other for-profit organizations (including those that are not small businesses) are eligible.
Are state and local government entities eligible?
Yes. Eligible applicants include state and local governments, such as county and city governments and special district governments.
Are tribal governments and tribal organizations eligible?
Yes. Federally recognized tribal governments and other tribal organizations are listed as eligible applicants.
Are U.S. territories or possessions eligible?
Yes. U.S. territories or possessions are highlighted among eligible applicants.
Are minority-serving institutions specifically mentioned as eligible?
Yes. The eligibility list highlights institutions such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian-serving institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).
Are faith-based or community-based organizations eligible?
Yes. Faith-based or community-based organizations are specifically mentioned among eligible applicants.
Are foreign components allowed?
Yes. Foreign components are allowed as defined in the NIH Grants Policy Statement, enabling collaborations when key expertise or resources are outside the United States.
What kind of overall projects are a good fit for this opportunity?
Projects that can credibly advance a candidate agent through discovery and preclinical development and, when justified, into early clinical proof-of-concept are a strong fit. Projects focused on tool compounds and ligands that strengthen target characterization and validation are also supported.
Where can the archived FOA be found?
The archived announcement was hosted by NIH at http://grants.nih.gov/grants/guide/pa-files/PAR-14-184.html.
Where is technical access support directed?
Technical access support is routed through the NIH Office of Extramural Research webmaster contact.
Browse more opportunities from the same category: Education Health
Next opportunity: Cooperative Ecosystem Studies Unit, Piedmont South Atlantic Coast
Previous opportunity: Basin States Salinity Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 14 184
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 14 184) also looked into and applied for these:
| Funding Opportunity |
|---|
| Revisions to Add Biomedical Big Data Training to Active NLM Institutional Training Grants in Biomedical Informatics (T15) Apply for RFA HG 14 006 Funding Number: RFA HG 14 006 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NIDA Core Center of Excellence Grant Program (P30) Apply for PAR 14 186 Funding Number: PAR 14 186 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Lasker Clinical Research Scholars Program (Si2) Apply for RFA OD 14 004 Funding Number: RFA OD 14 004 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NLM Information Resource Grants to Reduce Health Disparities (G08) Apply for RFA LM 14 001 Funding Number: RFA LM 14 001 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Wild Horse and Burro Contraception Apply for L14AS00048 Funding Number: L14AS00048 Agency: Bureau of Land Management Category: Education Health Funding Amount: $500,000 |
| Chronic Wounds Advancing the Science from Prevention to Healing (R01) Apply for RFA NR 15 001 Funding Number: RFA NR 15 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Long Term Retention in Care for U.S. Substance Using Populations (R34) Apply for PA 14 222 Funding Number: PA 14 222 Agency: National Institutes of Health Category: Education Health Funding Amount: $225,000 |
| Long Term Retention in Care for U.S. Substance Using Populations (R21) Apply for PA 14 223 Funding Number: PA 14 223 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Long Term Retention in Care for U.S. Substance Using Populations (R01) Apply for PA 14 224 Funding Number: PA 14 224 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Clinical Evaluation of Adjuncts to Opioid Therapies for the Treatment of Chronic Pain (R01) Apply for PAR 14 225 Funding Number: PAR 14 225 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exploratory Studies of Smoking Cessation Interventions for People with Schizophrenia (R21/R33) Apply for PAR 14 230 Funding Number: PAR 14 230 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exploratory Studies of Smoking Cessation Interventions for People with Schizophrenia (R33) Apply for PAR 14 231 Funding Number: PAR 14 231 Agency: National Institutes of Health Category: Education Health Funding Amount: $225,000 |
| National Cooperative Drug Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (U19) Apply for PAR 14 234 Funding Number: PAR 14 234 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Collaborative Research Projects to Enhance Applicability of Mouse Models for Translational Research (Collaborative R01) Apply for PAR 14 240 Funding Number: PAR 14 240 Agency: National Institutes of Health Category: Education Health Funding Amount: $450,000 |
| Research Projects to Enhance Applicability of Mouse Models for Translational Research (R01) Apply for PAR 14 241 Funding Number: PAR 14 241 Agency: National Institutes of Health Category: Education Health Funding Amount: $450,000 |
| Oncology Models Forum (U24) Apply for PAR 14 239 Funding Number: PAR 14 239 Agency: National Institutes of Health Category: Education Health Funding Amount: $750,000 |
| Limited Competition Biospecimen Banks to Support NCI Clinical Trials Network (NCTN) (U24) Apply for RFA CA 14 501 Funding Number: RFA CA 14 501 Agency: National Institutes of Health Category: Education Health Funding Amount: $11,750,000 |
| Molecular and Cellular Characterization of Screen Detected Lesions Coordinating Center and Data Management Group (U01) Apply for RFA CA 14 011 Funding Number: RFA CA 14 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Molecular and Cellular Characterization of Screen Detected Lesions (U01) Apply for RFA CA 14 010 Funding Number: RFA CA 14 010 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Innovation Corps (I Corps) Team Training Pilot Program for NIH Phase I Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Grantees (Admin Supp) Apply for PAR 14 261 Funding Number: PAR 14 261 Agency: National Institutes of Health Category: Education Health Funding Amount: $25,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 14 184", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.